These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17397004)

  • 1. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
    Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
    J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.
    Keller MJ; Guzman E; Hazrati E; Kasowitz A; Cheshenko N; Wallenstein S; Cole AL; Cole AM; Profy AT; Wira CR; Hogarty K; Herold BC
    AIDS; 2007 Feb; 21(4):467-76. PubMed ID: 17301565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.
    Fichorova RN; Tucker LD; Anderson DJ
    J Infect Dis; 2001 Aug; 184(4):418-28. PubMed ID: 11471099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides.
    Li LZ; Yang Y; Yuan SH; Wan YM; Qiu C; Feng YL; Xu JQ; Zhang XY
    Chin Med J (Engl); 2010 Dec; 123(23):3381-8. PubMed ID: 22166518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
    Wilson SS; Cheshenko N; Fakioglu E; Mesquita PM; Keller MJ; Herold BC
    Antivir Ther; 2009; 14(8):1113-24. PubMed ID: 20032541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
    Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.
    Bourne N; Bernstein DI; Ireland J; Sonderfan AJ; Profy AT; Stanberry LR
    J Infect Dis; 1999 Jul; 180(1):203-5. PubMed ID: 10353881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entry of inflammatory cells into the mouse vagina following application of candidate microbicides: comparison of detergent-based and sulfated polymer-based agents.
    Milligan GN; Dudley KL; Bourne N; Reece A; Stanberry LR
    Sex Transm Dis; 2002 Oct; 29(10):597-605. PubMed ID: 12370527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbicides for preventing transmission of genital herpes.
    Zeitlin L; Whaley KJ
    Herpes; 2002 Apr; 9(1):4-9. PubMed ID: 11916493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection.
    Zalenskaya IA; Cerocchi OG; Joseph T; Donaghay MA; Schriver SD; Doncel GF
    Am J Reprod Immunol; 2011 Jun; 65(6):569-77. PubMed ID: 21241401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
    Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
    Segarra TJ; Fakioglu E; Cheshenko N; Wilson SS; Mesquita PM; Doncel GF; Herold BC
    PLoS One; 2011; 6(11):e27675. PubMed ID: 22096611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.
    Su HI; Schreiber CA; Fay C; Parry S; Elovitz MA; Zhang J; Shaunik A; Barnhart K
    Contraception; 2011 Nov; 84(5):525-32. PubMed ID: 22018129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.
    Aranha CC; Gupta SM; Reddy KV
    Cytokine; 2008 Jul; 43(1):63-70. PubMed ID: 18513989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
    van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
    Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
    Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical microbicides for the prevention of genital herpes infection.
    Keller MJ; Tuyama A; Carlucci MJ; Herold BC
    J Antimicrob Chemother; 2005 Apr; 55(4):420-3. PubMed ID: 15743896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
    Trifonova RT; Pasicznyk JM; Fichorova RN
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat.
    D'Cruz OJ; Uckun FM
    Toxicol Pathol; 2007 Dec; 35(7):910-27. PubMed ID: 18098038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety evaluation of the candidate vaginal microbicide C31G.
    Catalone BJ; Kish-Catalone TM; Neely EB; Budgeon LR; Ferguson ML; Stiller C; Miller SR; Malamud D; Krebs FC; Howett MK; Wigdahl B
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1509-20. PubMed ID: 15793133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.